

DOCKET NO.: CSKL0003-100**PATENT****REMARKS**


Claims 26-35 were pending in the present application. Claims 26, 29, 34, and 35 have been amended herein. No new matter has been added. Upon entry of the present amendment, claims 26-35 will remain pending.

Applicants thank the Examiner for the telephonic message left on February 6, 2006 with Applicants' undersigned representative. The Examiner indicated that the claims would be allowable if the term "cancer" was deleted from three types of cancer cells (leukemia, melanoma, and lymphoma) as it was considered to be repetitive. Applicants have amended the claims accordingly herein. No change in claim scope is intended.

The Examiner's telephonic message also stated that although the specification no longer designates any claim for priority, the fact that a previously executed and filed Declaration did contain a claim for priority necessitates a newly executed Declaration without the claim for priority. Applicants, however, submit that no new Declaration need be filed since the claim for priority must be made either in the specification or an Application Data Sheet. Indeed, the specification is devoid of any claim for priority and no Application Data Sheet has been filed. Thus, there is no current claim for priority. Should the Examiner insist that a new Declaration without a claim for priority be filed, Applicants will endeavor to do so as soon as possible.

In view of the foregoing, Applicants respectfully submit that the claims are in condition for allowance. An early notice of the same is earnestly solicited. The Examiner is invited to contact Applicants' undersigned representative at (215) 665-6914 if there are any questions regarding Applicants' claimed invention.

Respectfully submitted,


Paul K. Legaard, Ph.D.
Registration No. 38,534

Date: 8 February 2006
COZEN O'CONNOR, P.C.
1900 Market Street
Philadelphia, PA 19103-3508
Telephone: (215) 665-6914
Facsimile: (215) 701-2141